Compare Johnson & Johnson (JNJ) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs BlackRock TCP Capital Corp — how do they compare? Johnson & Johnson trades at $260.51 (market cap $626.09B), while BlackRock TCP Capital Corp trades at $3.9 (market cap $327.64M). The key difference: Johnson & Johnson is far larger — about 1910.9× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (19.46%). Which is the better fit depends on your goals.
| JNJ | TCPC | |
|---|---|---|
Market Cap | $626.09B | $327.64M |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $7.26 |
52-Week Low | $172.78 | $3.13 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
TCPC trades at $4.00, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a low P/B of 0.59 suggesting potential undervaluation amid financial challenges.
The outlook is mixed: strategic actions and dividend yield near 8.5% offer value, but persistent losses, class action lawsuits, and high P/S ratio pose significant risks. Analyst consensus is cautious with more holds than buys, reflecting uncertainty over the company's turnaround efforts and profitability path.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
